Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H) pyridone on hepatic stellate cells

Abstract

Abstract: AIM: To explore the mechanism of 1-(3-fluorophenyl)-5-methyl-2-(1H) pyridone (FMP) against hepatic fibrosis. METHODS: The inhibitory effect of FMP on hepatic stellate cells(HSC) proliferation was observed by MTT, and the expression levels of collagen type I, III protein of HSC were detected by immunocytochemistry. RESULTS: HSC proliferation was decreased after incubation with FMP for 48 h at the dosage range from 200 μg/mL to 600 μg/mL compared with that in control group, and FMP could also significantly decrease the protein expression of collagen type I, III at the dosage of 200 μg/mL. CONCLUSION: FMP can inhibit the proliferation of HSC and decrease the expression of type Ⅰ, Ⅲ collagen, which are related to the mechanism of FMP treating hepatic fibrosis.

Key words: 1-(3-fluorophenyl)-5-methyl-2-(1H) pyridone, hepatic stellate cell, hepatic fibrosis

CLC Number:

R965.2

LI Ping, TAO Li-jian, HU Guo-ling, TAN De-ming. Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H) pyridone on hepatic stellate cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 782-785.

References

1 Friedman SL.Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury[J].J Biol Chem, 2000; 275:2247-2250.
2 Friedman SL, Maher JJ, Bissel M.Mechanisms and therapy of hepatic fibrosis:report of the AASLD single topic basic research conference[J].Hepatology, 2000;32:1403-1408.
3 Card JW, Racz WJ, Brien JF, et al.Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity[J]. Toxicol Sci, 2003;75:169-180.
4 Giri SN, Al-Bayati MA, Du X, et al.Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats [J].Cancer Chemother Pharmacol, 2004;53:141-150.
5 Tsuchiya H, Kaibori M, Yanagida H, et al.Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats[J].J Hepatol, 2004;40:94-101.
6 Iyer SN, Wild JS, SchiedtMJ, et al.Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters [J].J Lab Clin Med, 1995;125:779-785.
7 Shimizu T, Fukagawa M, Kuroda T, et al.Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy[J].Kidney Int Suppl, 1997;52:S239-S243.
8 Shimizu T, Kuroda T, Hata S, et al.Pirfenidone improves renal function and fibrosis in the postobstructed kidney[J].Kidney Int, 1998;54:99-109.
9 Suga H, Teraoka S, Ota K, et al.Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats[J].Exp Toxicol Pathol, 1995;47:287-291.
10 Iyer SN, Gurujeyalakshmi G, Giri SN.Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis[J].J Pharmacol Exp Ther, 1999;289:211-218.
11 Nagai S, Hamada K, Shigematsu M, et al.Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis[J].Intern Med, 2002;41:1118-1123.
12 Dosanjh A, Ikonen T, Wan B, et al.Pirfenidone:A novel anti-fibrotic agent and progressive chronic allograft rejection[J]. Pulm Pharmacol Ther, 2002;15:433-437.
13 George J, Rao KR, Stem R, et al.Dimethylnitrosamine-induced liver injury in rats:the early deposition of collagen[J]. Toxicology, 2001;156:129-138.
14 Lieber CS.Prevention and treatment of liver fibrosis based on pathogenesis[J].Alcohol Clin Exp Res, 1999;23:944-949.
15 Eng FJ, Friedman SL.New insights into hepatic stellate cell activation:the simple becomes complex [J].Am J Physiol, 2000;279:G7-G11.
16 Tada S, Nakamuta M, Enjoji M, et al.Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats[J].Clin Exp Pharmacol Physiol, 2001;28:522-527.

[1]	WU Furong, NING Lijuan, ZHOU Ran. Protective effects of Xiaochaihu Decoction on chemical hepatic fibrosis in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 481-488.
[2]	XIE Jiali, LI Jun. Endoplasmic reticulum stress-induced apoptosis up-regulation of DR5 via a CHOP-dependent mechanism in HSC-T6 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 159-166.
[3]	HE Yang, SONG Liying, PENG Xiangdong, FANG Weijin, WANG Chunjiang, DENG Zhenzhen, LIU Shikun. Protective effects of Cordyceps sinensis powder on liver injury induced by DEN in rats and the effect of TGF-β1/Smads pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 974-982.
[4]	ZENG Xi, HUYANG Liuzi, WU Yamin, CHEN Zhiheng. Protective effect of omega-3 fatty acids on hepatic fibrosis of rats induced by thioacetamide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 892-898.
[5]	PAN Chun-xiao, TANG Jie, WANG Xiao-yu, WANG Wen, LIU Jia-li, WU Fan-rong, CHEN Fei-hu. Effects of acid-sensing ion channel 1a on acid-induced activation of Hepatic stellate cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 528-533.
[6]	SONG Li-ying, PENG Xiang-dong, WANG Chun-jiang, GUO Ren, LIU Shi-kun. Recent progress in the role of miRNA in hepatic stellate cells activation and the chronic hepatic diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1422-1428.
[7]	SUN Yong, HUANG Xiao-hua, SHEN Neng, TANG Hua-dong, REN Hong, PENG Ming-li. Effects of Curc-OEG on primary rat hepatic stellate cells in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1086-1092.
[8]	CHENG Zhi-yun, PENG Jun-chun, LV Ying-hui. Role of epithelial-mesenchymal transition in the liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 928-936.
[9]	WANG Zhi-yong, WU Jun-hua, WANG Yu-rong, YU De-cai, DING Yi-tao. Effects of tectorigenin on the secretion of extracellular matrix in Hepatic stellate cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 175-180.
[10]	DENG Yan-hong, SHEN Neng, LING Ning, HU Peng, REN Hong, TANG Hua-dong, PENG Ming-li. Efficacy of the Gurc-OEG on rat liver fibrosis induced by CCl₄ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 147-153.
[11]	CHEN Meng, MA Yong. Effects of prazosin and phenylephrine on the proliferation and apoptosis of rat hepatic stellate cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 981-985.
[12]	LAI Li-na, REN Ze-en, YANG Liu-xu, ZHANG Xiao-yi, WANG Li-min, FAN Yi-min. ERK1/2 signal transduction pathway in anti-proliferation effect of PDGF-BB on HSC cells treated with Artesunate [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(2): 126-129.
[13]	WANG Qi-zhao, LV Ying-hui, LI Zhao-fa, JIANG Nan, DIAO Yong, XU Rui-an. Construction, detection and analysis of the oxidative stress models of hepatic stellate cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(9): 1002-1007.
[14]	FANG Hui-long, WANG Jun-jie, CHEN Mei-zi, JIA Lei, LI Chun-wei. Experimental study on therapeutic effects of dihydromyricetin on hepatic fibrosis in murine schistosomiasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 381-384.
[15]	XU Xiao-bing, YANG Miao-fang, ZHU Ren-min. Advancement on the therapy of somatostatin on liver fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 707-710.